Harrington Discovery Institute at University Hospitals and the Alzheimer's Drug Discovery Foundation (ADDF) announce a joint request for proposals for the 2019 ADDF-Harrington Scholar Award. The ADDF-Harrington Scholar Award is designed to accelerate the translation of innovative research that could treat, prevent, or slow Alzheimer's disease or related dementias. This year's RFP seeks programs that focus on proteostasis targets in addition to other novel approaches for Alzheimer's disease and related dementias.
"This is our sixth year of collaborating with the Harrington Discovery Institute to offer this unique opportunity, giving researchers access to both funding resources as well as a team of industry experts for project support," says Howard Fillit, MD, Founding Executive Director and Chief Science Officer at the ADDF. "This year's award will emphasize the development of drugs for Alzheimer's disease and related dementias that affect proteostasis, in addition to other novel targets. We are at a pivotal time in Alzheimer's research, and now, more than ever, we need to push forward the opportunity for new drug discoveries."
"We are committed to advancing promising discoveries into medicines that will help treat or cure Alzheimer's disease," said Jonathan Stamler, MD, President, Harrington Discovery Institute and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at University Hospitals and Case Western Reserve University School of Medicine. "The partnership with ADDF is an important part of our strategy to bridge the gap between basic discovery and the clinical realm, in order to improve the lives of people living with Alzheimer's."
Applicants have the opportunity to receive:
- Financial support up to $600,000 over two years
- Drug development and project management support through Harrington Discovery Institute's Innovation Support Center
- Award is open to academic investigators at accredited medical centers, research institutions and universities in the United States and Canada
- Lead investigator must have an MD or PhD or equivalent
- Proposals should offer creative science or novel approaches to treat, prevent, or slow Alzheimer's disease or related dementias. (Researchers working on drug development programs that are relevant, but not presently focused on Alzheimer's disease, are encouraged to apply.)
Please note the following date:
Letters of Intent will be accepted through April 12, 2019 5:00 pm ET. Applications must be submitted online.
About the Harrington Discovery Institute
The Harrington Discovery Institute at University Hospitals in Cleveland, Ohio—part of The Harrington Project for Discovery & Development—aims to advance medicine and society by enabling our nation's most inventive scientists to turn their discoveries into medicines that improve human health. The institute was created in 2012 with a $50 million founding gift from the Harrington family and instantiates the commitment they share with University Hospitals to a Vision for a "Better World."
About The Harrington Project for Discovery & Development
The Harrington Project for Discovery & Development (The Harrington Project), founded in late February 2012 by the Harrington Family and University Hospitals of Cleveland, is a $300 million national initiative built to bridge the translational valley of death. It includes the Harrington Discovery Institute and BioMotiv, a for-profit, mission-aligned drug development company that accelerates early discovery into pharma pipelines.
For more information about The Harrington Project and the Harrington Discovery Institute, visit HarringtonDiscovery.org.